高甘油三酯血症急性胰腺炎肠黏液屏障损伤机制研究
该研究将24只SD大鼠随机分为对照组、胆源性急性胰腺炎(BAP)组、高甘油三酯血症(HTG)组和HTG-AP组,每组6只,建模后24小时处死。结果显示HTG-AP组胰腺病理评分高于BAP组(12.95±1.31 vs. 7.30±1.59,P<0.05),回肠CD4、CD8表达升高,sIgA降低,结肠ZO-1、Occludin表达降低,结肠黏液层变薄(10.20±4.69 μm vs. 16.80±4.38 μm),含黏液杯状细胞减少(4.30±1.34 vs. 7.52±1.93 cells/crypt),NLRP6与MUC2表达及共定位信号在HTG-AP组下降最明显。作者认为肠黏液屏障破坏可能是HTG-AP重症化的重要机制,NLRP6/MUC2轴可能作为潜在治疗靶点。
要点
- HTG-AP组胰腺病理评分12.95±1.31,高于BAP组的7.30±1.59(P<0.05),肠道炎症也最重。
- HTG-AP组回肠CD4/β-actin为6.664±0.034、CD8/β-actin为3.135±0.034,均高于BAP组(分别为3.524±0.042、1.118±0.028,P<0.05)。
- HTG-AP组回肠黏膜sIgA为150.00±44.72 ng/L,低于BAP组的410.00±54.89 ng/L(P<0.05)。
- HTG-AP组结肠黏液层厚度10.20±4.69 μm、含黏液杯状细胞4.30±1.34 cells/crypt,均低于BAP组(分别为16.80±4.38 μm、7.52±1.93 cells/crypt,P<0.05)。
- HTG-AP组结肠NLRP6与MUC2表达及共定位信号下降最明显,作者认为该轴可能是潜在治疗靶点。
适用人群与场景
- 雄性Sprague-Dawley大鼠,无特定病原体级,共24只,随机分为对照组、BAP组、HTG组和HTG-AP组,每组6只。
处置流程与药物剂量
- BAP组经胰胆管逆行注射3.5%牛磺胆酸钠,速度0.3 mL/min,剂量2 mL/kg,建立BAP模型。
- HTG组腹腔注射聚乙二醇-聚丙二醇嵌段共聚物0.50 g/kg,每日一次,连续7天,建立HTG模型。
- HTG-AP组在HTG模型建立后,于第8天腹腔注射雨蛙素50 μg/kg,每1小时一次,连续注射7天,诱导HTG-AP。
- 对照组腹腔注射等体积生理盐水2 mL/kg。
- 所有大鼠于建模后24小时处死。
研究设计与关键结果
- 研究类型为动物实验,24只雄性SD大鼠随机分为4组,每组6只。
- HTG-AP组胰腺病理评分高于BAP组(12.95±1.31 vs. 7.30±1.59,P<0.05),回肠和结肠炎症细胞浸润贯穿肠壁全层,隐窝杯状细胞大量丢失。
- HTG-AP组回肠CD4/β-actin和CD8/β-actin均高于BAP组(6.664±0.034 vs. 3.524±0.042;3.135±0.034 vs. 1.118±0.028,均P<0.05)。
- HTG-AP组回肠黏膜上清sIgA低于BAP组(150.00±44.72 ng/L vs. 410.00±54.89 ng/L,P<0.05)。
- HTG-AP组结肠ZO-1/β-actin和Occludin/β-actin均低于BAP组(0.46±0.13 vs. 0.59±0.20;0.33±0.12 vs. 0.60±0.07,均P<0.05)。
- HTG-AP组结肠黏液层厚度小于BAP组(10.20±4.69 μm vs. 16.80±4.38 μm,P<0.05),含黏液杯状细胞数少于BAP组(4.30±1.34 cells/crypt vs. 7.52±1.93 cells/crypt,P<0.05)。
- 与对照组相比,BAP、HTG和HTG-AP组结肠NLRP6与MUC2表达及共定位信号均下降,HTG-AP组下降最明显。
证据类型、等级与局限
- 证据类型:动物实验(大鼠模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为肠黏液屏障破坏可能是HTG-AP重症化的重要机制,NLRP6/MUC2轴可能作为潜在治疗靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the structural and functional alterations of intestinal goblet cells and the mucus barrier in rats with hypertriglyceridemia acute pancreatitis (HTG-AP), and to evaluate the potential mechanism involved in the progression to severe HTG-AP.
METHODS: Twenty-four specific pathogen-free male Sprague-Dawley rats were divided into control group, biliary acute pancreatitis (BAP) group, hypertriglyceridemia (HTG) group, and HTG-AP group using a random number table method, with six rats in each group. In the BAP group, the BAP model was established by retrograde injection of 3.5% sodium taurocholate (0.3 mL/min) at 2 mL/kg through the pancreaticobiliary duct. In the HTG group, a polyethylene glycol-polypropylene glycol block copolymer was administered intraperitoneally at 0.50 g/kg once daily for 7 days to establish the HTG model. In the HTG-AP group, after the HTG model had been established, caerulein was administered intraperitoneally at 50 μg/kg once every one hour on day eight, and injections were continued for 7 days to induce HTG-AP. The control group received an equal volume of normal saline (2 mL/kg). All rats were sacrificed at 24 hours after modeling. Hematoxylin-eosin (HE) staining was performed to assess histopathological changes in the pancreas, ileum, and colon, and pathological scores were calculated. Western blotting was performed to determine the expressions of CD4, CD8, ZO-1, and Occludin. Enzyme linked immunosorbent assay (ELISA) was performed to measure secretory immunoglobulin A (sIgA) level in intestinal mucosa. Alcian blue/periodic acid-Schiff (AB/PAS) staining was performed to evaluate mucus layer structure and to measure mucus layer thickness and goblet cell number. Double immunofluorescence staining was performed to detect NOD-like receptor protein 6 (NLRP6) and mucin 2 (MUC2) expression and their colocalization.
RESULTS: 1) Compared with the control group, the BAP, HTG, and HTG-AP groups showed intestinal inflammatory changes of varying degrees. The HTG-AP group exhibited the most severe intestinal inflammation, accompanied by extensive acinar necrosis, hemorrhage, and marked edema; the pancreatic histopathological score was higher in the HTG-AP group than that in the BAP group (12.95±1.31 vs. 7.30±1.59, P<0.05). In addition, inflammatory cell infiltration in the ileum and colon extended through the full thickness of the intestinal wall, with massive loss of crypt goblet cells. 2) Intestinal immune function and barrier function were impaired in the BAP, HTG, and HTG-AP groups, and the impairment was most pronounced in the HTG-AP group. Compared with the BAP group, the HTG-AP group showed higher CD4 and CD8 expressions in the ileum (CD4/β-actin: 6.664±0.034 vs. 3.524±0.042, CD8/β-actin: 3.135±0.034 vs. 1.118±0.028, both P<0.05), a lower sIgA level in ileal mucosal supernatant (ng/L: 150.00±44.72 vs. 410.00±54.89, P<0.05), and decreased ZO-1 and Occludin expressions in the colon (ZO-1/β-actin: 0.46±0.13 vs. 0.59±0.20, Occludin/β-actin: 0.33±0.12 vs. 0.60±0.07, both P<0.05). 3) AB/PAS staining showed that the mucus layer of the colonic mucosal epithelium was altered in the BAP, HTG, and HTG-AP groups; the HTG-AP group exhibited severe mucus layer injury with more evident mucus depletion in goblet cells. Compared with the BAP group, the HTG-AP group had a thinner colonic mucus layer (μm: 10.20±4.69 vs. 16.80±4.38, P<0.05) and fewer mucus-containing goblet cells (cells/crypt: 4.30±1.34 vs. 7.52±1.93, P<0.05). 4) Double immunofluorescence staining showed that, compared with the control group, colonic NLRP6 and MUC2 expression and their colocalization signals were decreased in the BAP, HTG, and HTG-AP groups, and the decrease was most evident in the HTG-AP group.
CONCLUSIONS: Disruption of the intestinal mucus barrier may be an important mechanism contributing to the progression to severe HTG-AP, and the NLRP6/MUC2 axis may serve as a potential therapeutic target.
参考来源
- Du J, Qian Y, Xu Y, et al. [The investigation of the mechanism underlying the impairment of the intestinal mucous barrier in severe hypertriglyceridemia acute pancreatitis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 41876242. doi:10.3760/cma.j.cn121430-20240719-00349
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。